Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Entrada Therapeutics (TRDA) Shares Outstanding (Weighted Average): 2020-2024

Historic Shares Outstanding (Weighted Average) for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to $37.4 million.

  • Entrada Therapeutics' Shares Outstanding (Weighted Average) rose 1.65% to $38.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.0 million, marking a year-over-year increase of 1.65%. This contributed to the annual value of $37.4 million for FY2024, which is 12.14% up from last year.
  • Entrada Therapeutics' Shares Outstanding (Weighted Average) amounted to $37.4 million in FY2024, which was up 12.14% from $33.4 million recorded in FY2023.
  • In the past 5 years, Entrada Therapeutics' Shares Outstanding (Weighted Average) registered a high of $37.4 million during FY2024, and its lowest value of $28.3 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $33.4 million (2023), whereas its average is $34.6 million.
  • Data for Entrada Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY grew of 12.14% (in 2024) over the last 5 years.
  • Entrada Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $28.3 million in 2020, then climbed by 10.24% to $31.2 million in 2021, then rose by 5.97% to $33.1 million in 2022, then grew by 0.88% to $33.4 million in 2023, then grew by 12.14% to $37.4 million in 2024.